Mutagenicity, carcinogenicity and teratogenicity of beryllium.
The carcinogenicity of a number of beryllium compounds has been confirmed in experiments on laboratory animals and this metal has to be treated as a possible carcinogenic threat to man. These carcinogenic properties are associated with mutagenic activity as shown by the results of short-term tests performed in vitro with beryllium chloride and beryllium sulfate. These soluble beryllium compounds can produce some infidelity of in vitro synthesis, forward gene mutations in microorganisms and in mammalian cells. They are also able to induce cell transformation. In addition to the positive results obtained in several short-term assays beryllium compounds have been found to bind to nucleoproteins, to inhibit certain enzymes needed for DNA synthesis, to bind nucleic acids to cell membranes and to inhibit microtubule polymerization. The teratogenicity of beryllium salts is relatively unknown and needs additional investigation.
D000818:Animals; D001608:Beryllium / Q000633:toxicity*; D002273:Carcinogens; D004249:DNA Damage; D006801:Humans; D009153:Mutagens; D013723:Teratogens
D002273:Carcinogens; D009153:Mutagens; D013723:Teratogens; D001608:Beryllium